Literature DB >> 20140890

General exposures to prescription medications by race/ethnicity in a population-based sample: results from the Boston Area Community Health Survey.

Susan A Hall1, Gretchen R Chiu, David W Kaufman, Judith P Kelly, Carol L Link, Varant Kupelian, John B McKinlay.   

Abstract

PURPOSE: Few recent U.S. studies have examined population-based patterns in prescription drug use and even fewer have considered detailed patterns by race/ethnicity. In a representative community sample, our objectives were to determine the most commonly used prescription drug classes, and to describe their use by age, gender, and race/ethnicity.
METHODS: Cross-sectional epidemiologic study of 5503 (1767 black, 1877 Hispanic, 1859 white) community-dwelling participants aged 30-79 in the Boston Area Community Health (BACH) Survey (2002-2005). Using medication information collected from an in-home interview and medication inventory, the prevalence of use of a therapeutic class (95% confidence interval (95%CI)) in the past month was estimated by gender, age group, and race/ethnicity. Estimates were weighted inversely to the probability of sampling for generalizablity to Boston, MA.
RESULTS: The therapeutic class containing selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants was most commonly used (14.6%), followed by statins (13.9%), beta-adrenergic blockers (10.6%), and angiotensin-converting enzyme (ACE) inhibitors (10.5%). Within all age groups and both genders, black participants were substantially less likely than white to use SSRI/SNRI antidepressants (e.g., black men: 6.0% [95%CI: 3.9-8.1%]; white men: 15.0% [95%CI: 10.2-19.4%]). Other race/ethnic differences were observed: for example, black women were significantly less likely than other groups to use benzodiazepines (e.g., black: 2.6% [95%CI: 1.2-3.9%]; Hispanic: 9.4% [95%CI: 5.8-13.0%]).
CONCLUSIONS: Race/ethnic differences in use of prescription therapeutic classes were observed in our community sample. Examining therapeutic classes rather than individual drugs resulted in a different distribution of common exposures compared to other surveys.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20140890      PMCID: PMC3538828          DOI: 10.1002/pds.1920

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  14 in total

1.  Measuring the urologic iceberg: design and implementation of the Boston Area Community Health (BACH) Survey.

Authors:  John B McKinlay; Carol L Link
Journal:  Eur Urol       Date:  2007-03-19       Impact factor: 20.096

2.  Trends in psychotropic medication use among U.S. adults.

Authors:  Ryne Paulose-Ram; Marc A Safran; Bruce S Jonas; Qiuping Gu; Denise Orwig
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-05       Impact factor: 2.890

3.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

4.  A revised CES-D measure of depressive symptoms and a DSM-based measure of major depressive episodes in the elderly.

Authors:  C L Turvey; R B Wallace; R Herzog
Journal:  Int Psychogeriatr       Date:  1999-06       Impact factor: 3.878

5.  Manual for scoring socioeconomic status for research on health behavior.

Authors:  L W Green
Journal:  Public Health Rep       Date:  1970-09       Impact factor: 2.792

6.  Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey.

Authors:  David W Kaufman; Judith P Kelly; Lynn Rosenberg; Theresa E Anderson; Allen A Mitchell
Journal:  JAMA       Date:  2002-01-16       Impact factor: 56.272

7.  The acceptability of treatment for depression among African-American, Hispanic, and white primary care patients.

Authors:  Lisa A Cooper; Junius J Gonzales; Joseph J Gallo; Kathryn M Rost; Lisa S Meredith; Lisa V Rubenstein; Nae-Yuh Wang; Daniel E Ford
Journal:  Med Care       Date:  2003-04       Impact factor: 2.983

8.  Ethnicity and preferences for depression treatment.

Authors:  Jane L Givens; Thomas K Houston; Benjamin W Van Voorhees; Daniel E Ford; Lisa A Cooper
Journal:  Gen Hosp Psychiatry       Date:  2007 May-Jun       Impact factor: 3.238

9.  Comparing sources of drug data about the elderly.

Authors:  R E Johnson; W M Vollmer
Journal:  J Am Geriatr Soc       Date:  1991-11       Impact factor: 5.562

10.  Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States.

Authors:  Dima M Qato; G Caleb Alexander; Rena M Conti; Michael Johnson; Phil Schumm; Stacy Tessler Lindau
Journal:  JAMA       Date:  2008-12-24       Impact factor: 56.272

View more
  10 in total

1.  Commonly used antihypertensives and lower urinary tract symptoms: results from the Boston Area Community Health (BACH) Survey.

Authors:  Susan A Hall; Gretchen R Chiu; David W Kaufman; Gary A Wittert; Carol L Link; John B McKinlay
Journal:  BJU Int       Date:  2011-09-27       Impact factor: 5.588

2.  Associations of commonly used medications with urinary incontinence in a community based sample.

Authors:  Susan A Hall; May Yang; Margaret A Gates; William D Steers; Sharon L Tennstedt; John B McKinlay
Journal:  J Urol       Date:  2012-05-15       Impact factor: 7.450

3. 

Authors:  Berrin Günaydın; Ömer Kurtipek
Journal:  Turk J Anaesthesiol Reanim       Date:  2018-06-01

4.  Impact of race on cumulative exposure to antihypertensive medications in dialysis.

Authors:  James B Wetmore; Jonathan D Mahnken; Sally K Rigler; Edward F Ellerbeck; Purna Mukhopadhyay; Qingjiang Hou; Theresa I Shireman
Journal:  Am J Hypertens       Date:  2012-12-28       Impact factor: 2.689

5.  Benzodiazepines, Codispensed Opioids, and Mortality among Patients Initiating Long-Term In-Center Hemodialysis.

Authors:  Abimereki D Muzaale; Matthew Daubresse; Sunjae Bae; Nadia M Chu; Krista L Lentine; Dorry L Segev; Mara McAdams-DeMarco
Journal:  Clin J Am Soc Nephrol       Date:  2020-05-26       Impact factor: 8.237

6.  Racial/Ethnic Differences in Prenatal Supplement and Medication Use in Low-Risk Pregnant Women.

Authors:  Yassaman Vafai; Edwina H Yeung; Rajeshwari Sundaram; Melissa M Smarr; Nicole Gerlanc; William A Grobman; Daniel Skupski; Edward K Chien; Stefanie N Hinkle; Roger B Newman; Deborah A Wing; Angela C Ranzini; Anthony Sciscione; Jagteshwar Grewal; Cuilin Zhang; Katherine L Grantz
Journal:  Am J Perinatol       Date:  2020-10-08       Impact factor: 3.079

7.  Cohort profile: the Boston Area Community Health (BACH) survey.

Authors:  Rebecca S Piccolo; Andre B Araujo; Neil Pearce; John B McKinlay
Journal:  Int J Epidemiol       Date:  2012-12-05       Impact factor: 7.196

Review 8.  Prevalence and overlap of childhood and adult physical, sexual, and emotional abuse: a descriptive analysis of results from the Boston Area Community Health (BACH) survey.

Authors:  Gretchen R Chiu; Karen E Lutfey; Heather J Litman; Carol L Link; Susan A Hall; John B McKinlay
Journal:  Violence Vict       Date:  2013

9.  Benzodiazepine use among adults residing in the urban settlements of Karachi, Pakistan: a cross sectional study.

Authors:  Saleem P Iqbal; Syed Ahmer; Salima Farooq; Yasmin Parpio; Ambreen Tharani; Rashid A M Khan; Mohammad Zaman
Journal:  Subst Abuse Treat Prev Policy       Date:  2011-08-01

10.  Comparison of fetal growth by maternal prenatal acetaminophen use.

Authors:  Melissa M Smarr; Joe Bible; Nicole Gerlanc; Germaine M Buck Louis; Alaina Bever; Katherine L Grantz
Journal:  Pediatr Res       Date:  2019-03-25       Impact factor: 3.756

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.